Triumph Capital Management Aligos Therapeutics, Inc. Transaction History

Triumph Capital Management

  • $361 Million
  • Q3 2025

A detailed history of Triumph Capital Management transactions in Aligos Therapeutics, Inc. stock. As of the latest transaction made, Triumph Capital Management holds 90 shares of ALGS stock, worth $596. This represents 0.0% of its overall portfolio holdings.

Number of Shares
90
Holding current value
$596
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025
BUY
$7.31 - $11.39 $657 - $1,025
90 New
90 $0

Others Institutions Holding ALGS

# of Institutions
1
Shares Held
227K
Call Options Held
0
Put Options Held
0
View Full List

About Aligos Therapeutics, Inc.

ALGS Quotes by TradingView
  • Ticker ALGS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,717,000
  • Market Cap $263M
  • Description
  • Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...
More about ALGS
Track This Portfolio

Track Triumph Capital Management Portfolio

Follow Triumph Capital Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Triumph Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Triumph Capital Management with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email